Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed

Area of Science:

• Oncology
• Vascular Biology
• Immunotherapy

Background:

• Solid tumor therapy relies on efficient drug delivery, but tumor physiology presents challenges like leaky yet disorganized vasculature and high interstitial fluid pressure, leading to poor drug penetration and treatment failure.
• Tumor vasculature, while allowing drug passage, exhibits heterogeneous blood flow and elevated interstitial pressure, hindering effective intratumoral drug accumulation.
• Targeting tumor vasculature offers advantages: accessibility, endothelial cell stability against resistance, and dual effects of enhancing chemotherapy and directly killing tumor cells.

Purpose of the Study:

• To explore the potential of manipulating tumor vasculature to improve chemotherapeutic drug delivery in solid tumors.
• To investigate the mechanisms and therapeutic potential of tumor necrosis factor alpha (TNF) in solid tumor treatment.
• To understand how TNF and similar agents can be utilized in combination immunotherapy strategies.

Main Methods:

• Review of existing literature on tumor physiology, drug delivery challenges, and vascular targeting strategies.
• Analysis of the direct and indirect mechanisms of action of tumor necrosis factor alpha (TNF) on solid tumors.
• Exploration of the potential for combining vascular-targeting agents with chemotherapy and immunotherapy.

Main Results:

• Tumor vasculature manipulation can overcome physiological barriers to enhance drug delivery.
• Targeting endothelial cells offers stability and dual therapeutic effects: improved chemotherapy and tumor cell killing.
• Tumor necrosis factor alpha (TNF) exhibits complex actions, including direct tumor cell killing and vasculature destruction.

Conclusions:

• Targeting tumor vasculature is a viable strategy to improve chemotherapeutic efficacy in solid tumors.
• Tumor necrosis factor alpha (TNF) and comparable agents hold significant promise for combination immunotherapy.
• Further research into the mechanisms of TNF is crucial for developing advanced combination treatment strategies.